These experimental payloads remove a motor protein needed for cell division. They differ from drugs that block the same motor without removing it.
An ASCO preclinical abstract described dKIF976, a cereblon-recruiting KIF11 degrader, and antibody conjugates with antigen-dependent protein degradation and cell-growth inhibition. KIF11 is also called Eg5 or kinesin spindle protein. The reported conjugate experiments were cellular studies; the abstract does not demonstrate clinical activity or an established safety advantage over KIF11 inhibitors.
Showing the technology this term belongs to: Antibody-drug conjugate (ADC).
Shares Degrader-antibody conjugate (DAC), Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/